Mismatch repair deficiency predicts response to HER2 blockade in HER2-negative breast cancer

被引：0
|
作者：
Haricharan, Svasti [1 ]
Punturi, Nindo [1 ]
Seker, Sinem [1 ]
Devarakonda, Vaishnavi [2 ]
Kalra, Rashi [2 ]
Chen, Ching-Hui [2 ]
Mazumder, Aloran [1 ]
Li, Shungqiang [3 ]
Primeau, Tina [3 ]
Ellis, Matthew [2 ]
Kavuri, Shyam [2 ]
机构：
[1] Sanford Burnham Prebys Med Discovery Inst, La Jolla, CA USA
[2] Baylor Coll Med, Houston, TX 77030 USA
[3] Washington Univ, St Louis, MO 63110 USA
来源：
CANCER RESEARCH | 2021年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PD8-05
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
    Bose, Ron
    Kavuri, Shyam M.
    Searleman, Adam C.
    Shen, Wei
    Shen, Dong
    Koboldt, Daniel C.
    Monsey, John
    Goel, Nicholas
    Aronson, Adam B.
    Li, Shunqiang
    Ma, Cynthia X.
    Ding, Li
    Mardis, Elaine R.
    Ellis, Matthew J.
    CANCER DISCOVERY, 2013, 3 (02) : 224 - 237
  • [22] Can breast cancer patients with HER2 dual-equivocal tumours be managed as HER2-negative disease?
    Tong, Yiwei
    Chen, Xiaosong
    Fei, Xiaochun
    Lin, Lin
    Wu, Jiayi
    Huang, Ou
    He, Jianrong
    Zhu, Li
    Chen, Weiguo
    Li, Yafen
    Shen, Kunwei
    EUROPEAN JOURNAL OF CANCER, 2018, 89 : 9 - 18
  • [23] A nomogram for predicting the HER2 status of circulating tumor cells and survival analysis in HER2-negative breast cancer
    Yang, Yuqin
    Li, Liudan
    Tian, Wenjing
    Qiao, Zhen
    Qin, Qi
    Su, Liqian
    Li, Peiqiu
    Chen, Weirong
    Zhao, Hong
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [24] The impact of low HER2 expression on clinical significances and outcomes in patients with HER2-negative early breast cancer
    Koi, Y.
    Tajiri, W.
    Kawasaki, J.
    Akiyoshi, S.
    Koga, C.
    Nakamura, Y.
    Taguchi, K.
    Tokunaga, E.
    ANNALS OF ONCOLOGY, 2023, 34 : S311 - S312
  • [25] The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status
    Nanae Horisawa
    Yayoi Adachi
    Daiki Takatsuka
    Kazuki Nozawa
    Yuka Endo
    Yuri Ozaki
    Kayoko Sugino
    Ayumi Kataoka
    Haruru Kotani
    Akiyo Yoshimura
    Masaya Hattori
    Masataka Sawaki
    Hiroji Iwata
    Breast Cancer, 2022, 29 : 234 - 241
  • [26] The frequency of low HER2 expression in breast cancer and a comparison of prognosis between patients with HER2-low and HER2-negative breast cancer by HR status
    Horisawa, Nanae
    Adachi, Yayoi
    Takatsuka, Daiki
    Nozawa, Kazuki
    Endo, Yuka
    Ozaki, Yuri
    Sugino, Kayoko
    Kataoka, Ayumi
    Kotani, Haruru
    Yoshimura, Akiyo
    Hattori, Masaya
    Sawaki, Masataka
    Iwata, Hiroji
    BREAST CANCER, 2022, 29 (02) : 234 - 241
  • [27] Targeted Therapy of HER2-Negative Breast Cancer
    Schuetz, Florian
    Domschke, Christoph
    Schneeweiss, Andreas
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (03) : 118 - 121
  • [28] Adjuvant capecitabine for HER2-negative breast cancer
    Burki, Talha Khan
    LANCET ONCOLOGY, 2017, 18 (07): : E375 - E375
  • [29] Anthracyclines in the treatment of HER2-negative breast cancer
    Paik, Soonmyung
    Taniyama, Yusuke
    Geyer, Charles E., Jr.
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2008, 100 (01): : 2 - 4
  • [30] Bevacizumab in the treatment of HER2-negative breast cancer
    Lorusso, Vito
    BIOLOGICS-TARGETS & THERAPY, 2008, 2 (04): : 813 - 821
12345